Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells

about

Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells

Item

http://www.wikidata.org/entity/Q58798568

description

scientific article published on 01 May 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2018

@uk

name

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@en

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@nl

type

Item

label

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@en

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@nl

prefLabel

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@en

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@nl

P1476

Pixantrone, a new anticancer d ...... non-differentiated H9c2 cells

@en

P2093

Ana Reis-Mendes

http://www.w3.org/2001/XMLSchema#string

Marisa Alves

http://www.w3.org/2001/XMLSchema#string

P2860

A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1α expression and mitochondrial biogenesis

Neutral red uptake assay for the estimation of cell viability/cytotoxicity

A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes.

Mitoxantrone: an active new agent in the treatment of advanced breast cancer.

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

P304

13-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2478/INTOX-2018-0002

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vera Marisa Costa

Fernando Remião

Maria de Lourdes Bastos

Félix Carvalho

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30181708

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

toxicology

P932

6117818

http://www.w3.org/2001/XMLSchema#string